Literature DB >> 7947379

Improvement of ischemic myocardial dysfunction by nisoldipine.

K Saida1, M Umeda, A Itakura.   

Abstract

We examined the cardioprotective effect of nisoldipine against myocardial dysfunction during ischemia and reperfusion in Langendorff perfused rabbit hearts. Nisoldipine was administered to the hearts before 60 minutes of global ischemia. This agent inhibited the increase of end-diastolic pressure during ischemia and also improved the recovery of left ventricular developed pressure and coronary flow during reperfusion in a concentration-dependent manner. The maximal cardioprotective effect was observed in 10(-8) M nisoldipine. The beneficial effect was associated with an increase of coronary flow during reperfusion. Therefore, both the nisoldipine-increased coronary flow during reperfusion and the inhibition of ischemic contracture by nisoldipine seem to play a crucial role in improving myocardial dysfunction of ischemic-reperfused hearts.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7947379     DOI： 10.1007/bf00877321

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN： 0920-3206            Impact factor:   3.727


  22 in total

1.  Direct measurement of changes in intracellular calcium transients during hypoxia, ischemia, and reperfusion of the intact mammalian heart.

Authors:  Y Kihara; W Grossman; J P Morgan
Journal:  Circ Res       Date:  1989-10       Impact factor: 17.367

Review 2.  The no-reflow phenomenon in ischemic myocardium.

Authors:  J B Gavin; S M Humphrey; P B Herdson
Journal:  Int Rev Exp Pathol       Date:  1983

3.  Effects of nisoldipine, a new calcium antagonist, on myocardial infarct size and cardiac dynamics following acute myocardial infarction.

Authors:  J Tumas; R Deth; R A Kloner
Journal:  J Cardiovasc Pharmacol       Date:  1985 Mar-Apr       Impact factor: 3.105

Review 4.  Actions of nisoldipine in cardiovascular disease.

Authors:  D J Duncker; L J Van Woerkens; P W Serruys; J R Roelandt; P G Hugenholtz; P D Verdouw
Journal:  Can J Cardiol       Date:  1989 Jun-Aug       Impact factor: 5.223

5.  Correlation between cytosolic free calcium, contracture, ATP, and irreversible ischemic injury in perfused rat heart.

Authors:  C Steenbergen; E Murphy; J A Watts; R E London
Journal:  Circ Res       Date:  1990-01       Impact factor: 17.367

6.  Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylate (Nisoldipine, Bay k 5552).

Authors:  S Kazda; B Garthoff; H Meyer; K Schlossmann; K Stoepel; R Towart; W Vater; E Wehinger
Journal:  Arzneimittelforschung       Date:  1980

7.  Timely administration of nisoldipine essential for prevention of myocardial ATP catabolism.

Authors:  J W De Jong
Journal:  Eur J Pharmacol       Date:  1985-11-26       Impact factor: 4.432

8.  Reduced glycolysis by nisoldipine treatment of ischemic heart.

Authors:  J W de Jong; T Huizer
Journal:  J Cardiovasc Pharmacol       Date:  1985 May-Jun       Impact factor: 3.105

Review 9.  Influence of calcium channel antagonist therapy on the ischemic response to acute coronary occlusion in humans.

Authors:  M J Kern
Journal:  Clin Cardiol       Date:  1989-07       Impact factor: 2.882

10.  A low concentration of nisoldipine reduces ischemic heart injury: enhanced reflow and recovery of contractile function without energy preservation during ischemia.

Authors:  J A Watts; J P Whipple; A A Hatley
Journal:  J Mol Cell Cardiol       Date:  1987-08       Impact factor: 5.000
View more
  1 in total

1.  Effects of salvianolic acid B on L-type calcium channels and myocardial contractility in isolated rat ventricular myocytes and hERG K+ channels expressed in HEK293 cells.

Authors:  Qiongtao Song; Xue Han; Yuchong Xue; Tao Song; Xi Chu; Xuan Zhang; Yuanyuan Zhang; Ying Zhang; Jianping Zhang; Li Chu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-05-05       Impact factor: 3.000
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.